Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 22, Issue 5, Pages 655-664
Publisher
Elsevier BV
Online
2021-04-14
DOI
10.1016/s1470-2045(21)00081-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
- (2020) Corneel Coens et al. LANCET ONCOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- (2019) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
- (2018) Andrew Bottomley et al. Clinical Trials
- Health-Related Quality of Life in Cancer Patients Treated with PD-(L)1 Inhibitors: A Systematic Review
- (2018) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma
- (2018) Jammbe Z. Musoro et al. EUROPEAN JOURNAL OF CANCER
- General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
- (2018) S. Nolte et al. EUROPEAN JOURNAL OF CANCER
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
- (2017) Teresa M. Petrella et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life results from the phase III CheckMate 067 study
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- (2017) Corneel Coens et al. LANCET ONCOLOGY
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
- (2016) G. V. Long et al. ANNALS OF ONCOLOGY
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
- (2016) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
- (2016) Andrew Bottomley et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Reporting of Patient-Reported Outcomes in Randomized Trials
- (2013) Melanie Calvert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
- (2009) Andrew Bottomley et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now